PMID- 38329551
OWN - NLM
STAT- MEDLINE
DCOM- 20240209
LR  - 20240324
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Print)
IS  - 0171-5216 (Linking)
VI  - 150
IP  - 2
DP  - 2024 Feb 8
TI  - CircBRIP1: a plasma diagnostic marker for non-small-cell lung cancer.
PG  - 83
LID - 10.1007/s00432-023-05558-5 [doi]
LID - 83
AB  - BACKGROUND: Circular RNA (circRNA), which has been demonstrated in studies to be 
      abundantly prevalent in tumor cells and bodily fluids and to play a significant 
      role in tumors, has the potential for biological markers to be used to assist 
      tumor diagnosis. This study mainly discusses the potential of circBRIP1 as a 
      biomarker for diagnosing non-small-cell lung cancer (NSCLC). METHODS: First, 
      high-throughput sequencing screened the differentially expressed circBRIP1, and 
      real-time fluorescence quantitative PCR (qRT-PCR) verified its expression in 
      NSCLC. Next, sanger sequencing, agarose gel electrophoresis, RNase R assay, and 
      fluorescence in situ hybridization (FISH) were used to verify its molecular 
      characteristics. The diagnostic value was analyzed by the subject operating 
      characteristic curve (ROC), and the cardinality test was analyzed for correlation 
      with clinicopathological parameters. Finally, we tentatively predicted the 
      downstream miRNA- or RNA-binding protein that may bind to circBRIP1. RESULTS: 
      CircBRIP1 is highly expressed in NSCLC tissues, cells and plasma with good 
      specificity and stability. CircBRIP1 not only can well-distinguish NSCLC patients 
      from benign pulmonary diseases (BPD) patients, healthy individuals and small cell 
      lung cancer (SCLC) patients, but it also has some potential for dynamic 
      monitoring. Combined with the analysis of clinicopathological data, the high 
      level of circRNA expression was related to the degree of tumor differentiation, 
      TNM stage, T stage, lymph node metastasis and distal metastasis in NSCLC 
      patients. In addition, circBRIP1 has a high diagnostic value. CONCLUSIONS: Plasma 
      circBRIP1 is significantly overexpressed in NSCLC patients. It can be used as a 
      sensitive biomarker with unique value for early diagnosis, tumor development and 
      prognosis detection.
CI  - (c) 2024. The Author(s).
FAU - Fan, Xinfeng
AU  - Fan X
AD  - Department of Laboratory Medicine, Affiliated Hospital of Nantong University, 
      Medical School of Nantong University, Nantong, 226001, Jiangsu, China.
AD  - Medical School of Nantong University, Nantong University, Nantong, China.
AD  - Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, 
      Nantong, 226001, Jiangsu, China.
FAU - Zhang, Qi
AU  - Zhang Q
AD  - Department of Laboratory Medicine, Affiliated Hospital of Nantong University, 
      Medical School of Nantong University, Nantong, 226001, Jiangsu, China.
AD  - Medical School of Nantong University, Nantong University, Nantong, China.
AD  - Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, 
      Nantong, 226001, Jiangsu, China.
FAU - Qin, Shiyi
AU  - Qin S
AD  - Department of Laboratory Medicine, Affiliated Hospital of Nantong University, 
      Medical School of Nantong University, Nantong, 226001, Jiangsu, China.
AD  - Medical School of Nantong University, Nantong University, Nantong, China.
AD  - Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, 
      Nantong, 226001, Jiangsu, China.
FAU - Ju, Shaoqing
AU  - Ju S
AD  - Department of Laboratory Medicine, Affiliated Hospital of Nantong University, 
      Medical School of Nantong University, Nantong, 226001, Jiangsu, China. 
      jsq814@hotmail.com.
AD  - Department of Laboratory Medicine, Affiliated Hospital of Nantong University, No. 
      20, Xisi Road, Nantong, 226001, Jiangsu, China. jsq814@hotmail.com.
LA  - eng
GR  - 82272411/National Natural Science Foundation of China/
GR  - 82272411/National Natural Science Foundation of China/
GR  - 82272411/National Natural Science Foundation of China/
GR  - 82272411/National Natural Science Foundation of China/
PT  - Journal Article
DEP - 20240208
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
RN  - 0 (RNA, Circular)
RN  - 0 (Biomarkers)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Non-Small-Cell Lung/diagnosis/genetics
MH  - In Situ Hybridization, Fluorescence
MH  - RNA, Circular/genetics
MH  - *Lung Neoplasms/diagnosis/genetics
MH  - Biomarkers
PMC - PMC10853360
OTO - NOTNLM
OT  - Diagnosis
OT  - Non-small-cell lung cancer
OT  - Plasma biomarker
OT  - Prognosis
OT  - circBRIP1
COIS- The authors declare no competing interests. The authors claim to have no 
      conflicts of interest.
EDAT- 2024/02/08 12:42
MHDA- 2024/02/09 06:42
PMCR- 2024/02/08
CRDT- 2024/02/08 11:09
PHST- 2023/07/09 00:00 [received]
PHST- 2023/12/12 00:00 [accepted]
PHST- 2024/02/09 06:42 [medline]
PHST- 2024/02/08 12:42 [pubmed]
PHST- 2024/02/08 11:09 [entrez]
PHST- 2024/02/08 00:00 [pmc-release]
AID - 10.1007/s00432-023-05558-5 [pii]
AID - 5558 [pii]
AID - 10.1007/s00432-023-05558-5 [doi]
PST - epublish
SO  - J Cancer Res Clin Oncol. 2024 Feb 8;150(2):83. doi: 10.1007/s00432-023-05558-5.